Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC

Inclusion Criteria: * Non-small cell lung cancer confirmed by histology. * Tumor size is measured according to RECIST standard. * Unresectable stage IIIA (N2) and IIIB/IIIC, confirmed by PET-CT/or chest and abdomen CT, brain MRI, and whole body bone scan. * 18-75 years old, regardless of gender. * The ECOG score is 0-1. * Newly treated or underwent neoadjuvant chemotherapy and/or immunotherapy. * Have not received chest radiotherapy in the past. * Serum hemoglobin ≥10 mg/dL, platelets ≥100000/μL, absolute neutrophil count ≥1500/μL. * Serum creatinine ≤1.25 times UNL or creatinine clearance ≥60 ml/min. * Serum bilirubin ≤1.5 times UNL, AST (SGOT) and ALT (SGPT) ≤2.5 times UNL, alkaline phosphatase≤ 5 times UNL. * FEV1\>1 L. * CB6 normal range. * The patient and his family members agree and sign an informed consent form. Exclusion Criteria: * Other malignant tumors in the past or during treatment, except for non-melanoma of the skin or carcinoma in situ of the cervix. * Any other diseases or conditions are contraindications to chemotherapy (such as active infection, within 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy). * Pregnant or breastfeeding women, women who have not undergone a pregnancy test (within 14 days before the first dose), and pregnant women. * Those who are pregnant, breastfeeding or have fertility but have not taken contraceptive measures. * People with bleeding tendency. * Those who participated in other clinical trials within 30 days before participating in this experiment. * Drug addiction, long-term alcoholism, and AIDS patients. * People with uncontrollable seizures or loss of self-control due to mental illness. * People with a history of severe allergies or specific physique. * The researcher believes that the patient is inappropriate to participate in this trial. Exit criteria * The treatment cannot be carried out in accordance with the requirements of the research protocol; * The patient has an allergic reaction ≥ grade 4 or a serious adverse reaction to the study drug; * The patient is pregnant or has not used adequate contraceptive measures; * The researcher judges that the patient should not continue to participate the clinical trial; * The subject asked to withdraw.